A large trial established the favorable clinical profile of a new polymer-free biolimus-A9-eluting stent (PF-BES) with a 1-month dual antiplatelet therapy (DAPT) regimen in patients at high bleeding risk (HBR). We evaluated the real-world patterns of indications, DAPT strategies and outcomes for the PF-BES following this evidence.
Dual antiplatelet therapy strategies and clinical outcomes for a polymer-free biolimus A9-coated stent
Capodanno, Davide;
2019-01-01
Abstract
A large trial established the favorable clinical profile of a new polymer-free biolimus-A9-eluting stent (PF-BES) with a 1-month dual antiplatelet therapy (DAPT) regimen in patients at high bleeding risk (HBR). We evaluated the real-world patterns of indications, DAPT strategies and outcomes for the PF-BES following this evidence.File in questo prodotto:
Non ci sono file associati a questo prodotto.
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
